TP53 and myelodysplastic syndrome: Jadersten et al. observed TP53 mutations in 10/55 (18%) patients with low and intermediate-1 risk MDS carrying del(5q), which render them at higher risk for disease evolution to AML [527] Another investigation reported TP53 mutations in 17% of lower-risk MDS with isolated del(5q),associated with shorter survival [554].